Rising R&D, SG&A Costs Lead to Wider Q1 Net Loss for Rosetta Genomics | GenomeWeb
NEW YORK (GenomeWeb News) - Rosetta Genomics today said it generated no first-quarter sales, while its R&D spending climbed 30 percent, and its net loss increased 33 percent year over year.
 
Rosetta, which went public in February, said that R&D spending for the three months ended March 31, 2007, increased to $1.16 million from $886,000 in the year-ago period. R&D accounted for 52 percent of the company’s spending during the quarter.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.